REPL replimune.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The EV/EBITDA price chart for Replimune Group, Inc. (REPL) on the GURU.Markets platform is currently at 0.00. Replimune Group, Inc. (REPL) develops anti-tumor agents while adhering to strict environmental standards and bioethics. Business growth relies on partnerships with pharma behemoths for clinical trials; however, the high probability of clinical failure creates significant risks for invested capital.

For Replimune Group, Inc. (REPL), whose success depends on the outcomes of vaccine clinical trials, the EV/EBITDA multiple serves as a tool for valuing the business relative to its operating profit. This metric aggregates market capitalization and net debt, comparing them against earnings before depreciation and amortization. By analyzing the historical EV/EBITDA value, an investor can see the current level of 0.00, which reflects market expectations. This allows for an assessment of the company's resilience regardless of macroeconomic cycles.